Express News | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now?
Ladenburg Thalmann Maintains Viridian Therapeutics(VRDN.US) With Hold Rating
Ladenburg Thalmann analyst Michael Higgins maintains $Viridian Therapeutics(VRDN.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 34.3% and a total average return
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $30 to $46
On Jun 12, major Wall Street analysts update their ratings for $Viridian Therapeutics(VRDN.US)$, with price targets ranging from $30 to $46.Needham analyst Serge Belanger maintains with a buy rating,
Express News | Wolfe Research Initiates Coverage On Viridian Therapeutics With Outperform Rating
Viridian Therapeutics Price Target Maintained With a $30.00/Share by Needham
Viridian Therapeutics Price Target Maintained With a $30.00/Share by Needham
Viridian Gains After R&D Update; Wolfe Starts at Outperform
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Health care stocks were mixed premarket Tuesday, with the Health Care Select Sector SPDR Fund (XLV) was 0.1% higher and the iShares Biotechnology ETF (IBB) was down 0.5% recently. Viridian Therapeutic
Sector Update: Health Care
Health care stocks were leaning lower premarket Tuesday, with the Health Care Select Sector SPDR Fund (XLV) inactive and the iShares Biotechnology ETF (IBB) down 0.4%. Viridian Therapeutics (VRDN) sto
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as US FOMC Meeting Begins
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively traded Invesco QQQ Trust (QQQ) was also 0.3% lower in Tuesday's premarket activity as the US Federal O
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersViracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. The company's market cap stands at $26.7 million. Purple Biotech (NASDAQ:PPBT) stock in
Wolfe Research Initiates Coverage on Viridian Therapeutics With Outperform Rating, $29 Price Target
Viridian Therapeutics (VRDN) has an average rating of outperform and price targets ranging from $20 to $46, according to analysts polled by Capital IQ. Price: 13.76, Change: +1.54, Percent Change: +12
Viridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket
Viridian Therapeutics (VRDN) said Tuesday that it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August. The trials will asse
Express News | Viridian Therapeutics Gives Details About Phase 3 Clinical Trial For Patients With Active And Chronic Thyroid Eye Disease
Express News | Viridian Therapeutics Inc - Company Plans to Launch Vrdn-003 With a Commercially Available Autoinjector Pen
Express News | Viridian Therapeutics Inc - Vrdn-003 Biologics License Application (Bla) Submission Anticipated by Year-End 2026
Express News | Viridian Therapeutics Inc: On Track to Initiate Two Phase 3 Clinical Trials of Vrdn-003 in August 2024
Express News | Viridian Therapeutics Announces Details of Subcutaneous Vrdn-003 Phase 3 Clinical Program for Patients With Active and Chronic Moderate-to-Severe Thyroid Eye Disease
Wolfe Research Initiates Viridian Therapeutics(VRDN.US) With Buy Rating, Announces Target Price $29
Wolfe Research analyst Andy Chen initiates coverage on $Viridian Therapeutics(VRDN.US)$ with a buy rating, and sets the target price at $29.According to TipRanks data, the analyst has a success rate o
Express News | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)